CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
Simone C. Oostindie(Leiden University Medical Center), Ronald P. Taylor(University of Virginia), Frank J. Beurskens(Genmab (Netherlands)), Esther C.W. Breij(Genmab (Netherlands)), Rob N. de Jong(Genmab (Netherlands)), Jillian C. Tupitza(University of Virginia), Paul W.H.I. Parren(Leiden University Medical Center), Hilma J. van der Horst(Amsterdam University Medical Centers), Kristin Strumane(Genmab (Netherlands)), Clive S. Zent(University of Rochester Medical Center), Karl R. VanDerMeid(Unknown), Janine Schuurman(Genmab (Netherlands)), Erika M. Cook(University of Virginia), Margaret A. Lindorfer(University of Virginia), Richard Burack(University of Rochester Medical Center), Tuna Mutis(Amsterdam University Medical Centers), Martine E.D. Chamuleau(Hovon)
Cited by 62
Related Papers
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
|The Journal of Immunology|2010|1k
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy
|The Journal of Immunology|2004|149